Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

521
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
521
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

403
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
403
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

353
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
353

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Learning to see in the gray: Strategies for building critical analysis skills in the new ambulatory care practitioner.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Donanemab (Kisunla) for the Slowing of Alzheimer Disease.

American family physician·2025
Same author

Incretins for obesity: closer to a nicotine patch than a silver bullet.

Expert opinion on pharmacotherapy·2025
Same author

Lecanemab (Leqembi) for the Slowing of Alzheimer Disease.

American family physician·2025
Same author

Choose your own adventure: Perception of gamification in continuing pharmacy education.

Currents in pharmacy teaching & learning·2025
Same author

Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population.

The Annals of pharmacotherapy·2023

相关实验视频

Updated: Jul 25, 2025

Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

19.2K

一个新的配方:多尼佩西尔补丁

Megan Adelman1, Lora Louis2

  • 11 Cleveland Clinic Akron General, Center for Family Medicine, Akron, Ohio.

The Senior care pharmacist
|June 29, 2023
PubMed
概括

一个新的donepezil贴片为痴呆症提供了潜在的治疗选择,提高了耐受性,并帮助患有吞困难的患者. 与口服药物相比,这种配方可以减少副作用.

科学领域:

  • 神经科学和药理学 神经科学和药理学
  • 老年医学 老年医学

背景情况:

  • 全球痴呆症患病率正在上升,需要改进治疗策略.
  • 乙胆酶抑制剂是痴呆症的主要药物治疗方法,广泛使用的口服药物包括多内佩西尔,加兰他胺和里瓦斯蒂格明.
  • 现有的口服配方存在挑战,包括对某些患者的潜在副作用和管理困难.

研究的目的:

  • 审查一种新型多尼佩西尔贴片配方的疗效,安全性和耐受性.
  • 探索在痴呆症管理中使用新型多尼佩西尔贴片的临床考虑.
  • 评估对患有失调症和减少副作用负担的患者的潜在益处.

主要方法:

  • 文献审查和现有临床数据的分析.
  • 对新型多尼佩西尔贴片与口服配方的比较评估.
  • 评估安全概况,包括不良事件和耐受性.

主要成果:

  • 多尼佩西尔贴片的疗效与口服多尼佩西尔的疗效相当.
  • 补丁配方可以提供更好的耐受性和减少某些胃肠道副作用的发生率.
  • 它为患有失足症的患者提供了可行的替代方案.

结论:

更多相关视频

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
06:02

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Published on: December 26, 2016

10.4K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

相关实验视频

Last Updated: Jul 25, 2025

Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

19.2K
2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition
06:02

2-Methacryloyloxyethyl Phosphorylcholine Polymer Treatment of Complete Dentures to Inhibit Denture Plaque Deposition

Published on: December 26, 2016

10.4K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K
  • 这种新型的donepezil补丁代表了痴呆症药物治疗的重大进展.
  • 这种配方通过解决管理挑战和潜在地改善患者的坚持和结果来增强治疗选择.
  • 进一步的研究应该集中在长期疗效和现实世界的有效性.